Jennifer Porter, NP
Nurse Practitioner · Santa Fe, NMNPI 1922296656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$492
- Gilead$388
- Johnson & Johnson$255
- AstraZeneca$214
- AbbVie$197
- Bristol Myers Squibb$180
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,94091%
- Education$2789%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $492 |
| Gilead(2 entities) | 17 | $388 |
| Johnson & Johnson | 13 | $255 |
| AstraZeneca | 8 | $214 |
| AbbVie | 10 | $197 |
| Bristol Myers Squibb | 9 | $180 |
| Pfizer | 7 | $152 |
| Novocure Inc. | 1 | $131 |
| Amgen | 2 | $111 |
| EMD Serono, Inc. | 5 | $110 |
| Array Biopharma Inc | 6 | $109 |
| Genentech USA, Inc. | 6 | $107 |
| Boston Scientific | 4 | $104 |
| Incyte Corporation | 5 | $93 |
| Mirati Therapeutics, Inc. | 5 | $91 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Servier Pharmaceuticals LLC | 4 | $86 |
| Seagen Inc. | 5 | $71 |
| GSK | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Puma Biotechnology, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Tempus AI, Inc | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune Gio$131
How this compares
$3,219 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 24 | $412,453 |
| IbrancePalbociclib | 20 | $298,529 |
| XtandiEnzalutamide | 21 | $290,740 |
| CalquenceAcalabrutinib Maleate | 12 | $169,100 |
| BrukinsaZanubrutinib | 11 | $154,546 |
| GleevecImatinib Mesylate | 12 | $120,983 |
| SprycelDasatinib | 11 | $105,658 |
| Abiraterone Acetate | 37 | $68,040 |
| EliquisApixaban | 40 | $28,751 |
| XareltoRivaroxaban | 13 | $14,117 |
| Hydroxyurea | 33 | $1,054 |
| Anastrozole | 44 | $881 |
| Letrozole | 31 | $834 |
| Acyclovir | 36 | $813 |
| Tamoxifen Citrate | 30 | $721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $180 | $412,45324 claims |
| PfizerIbrance, Eliquis | $152 | $327,28060 claims |
| AstraZenecaCalquence | $214 | $169,10012 claims |
| NovartisGleevec | $492 | $120,98312 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $90 | $105,65811 claims |
| Johnson & JohnsonXarelto | $255 | $14,11713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Other nurse practitioner in Santa Fe
- Ryan CommiskeySanta Fe$18K
- Laura DevorSanta Fe$6K
- Jennifer PenningSanta Fe$5K
- Lissa ShafferSanta Fe$2K
- Eliezer PanganSanta Fe$2K
- Marisa EscobarAlbuquerque$36K
- Catherine SollerAlbuquerque$33K
- Lauren HeckethornRio Rancho$14K
- Christina ParksAlbuquerque$7K
- Paula JohnsonAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.